Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of adamgammadex sodium vs sugammadex for reversal of rocuronium-induced deep neuromuscular block (PTC 1–2)
CTR20213282Phase 3Completed
- Sponsor
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adamgammadex in neuromuscular block (NMB), sponsored by Zhejiang Xianju Pharmaceutical Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
adamgammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20213282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213282.